How Is a Pancreatic Biopsy Done and What Should I Expect?

A pancreatic biopsy is most commonly performed using endoscopic ultrasound, a procedure in which a thin, flexible scope is passed through your mouth and into the upper digestive tract while you are sedated. A small needle at the tip of the scope is guided into the pancreatic lesion under real-time ultrasound imaging, and tiny tissue samples are withdrawn. The whole process typically takes 30 to 60 minutes, and most people go home the same day. Less commonly, a needle is inserted through the skin under CT guidance instead. Either way, the goal is to get enough tissue for a pathologist to determine whether a mass is cancerous, benign, or something else entirely.

Why Endoscopic Ultrasound Is the Preferred Approach

The pancreas sits deep in the abdomen, tucked behind the stomach and surrounded by major blood vessels. That location makes it one of the harder organs to reach with a needle from outside the body. Endoscopic ultrasound, or EUS, gets around this by placing the ultrasound probe right next to the pancreas, inside the stomach or duodenum. From there, the needle only has to travel a short distance through the gut wall to reach the target. This close-range view gives EUS a diagnostic sensitivity above 90% for pancreatic tumors, and for small lesions under about 2 to 3 centimeters it can reach sensitivity near 99%, far outperforming CT scans for those early-stage masses.¹

Because the needle path is so short and stays within the gastrointestinal tract rather than crossing through skin, muscle, and abdominal organs, the risk of bleeding and other complications is low. A large meta-analysis pooling data from 78 cohort studies covering roughly 11,000 patients found that overall complication rates for EUS-guided pancreas biopsy were very low, with individual complications like bleeding, pancreatitis, infection, and perforation each occurring at near-zero pooled rates.²

What Happens Before the Procedure

You will be asked to stop eating and drinking for at least six to eight hours beforehand, since the scope needs a clear path through your upper digestive tract. Your medical team will review your medications, paying particular attention to blood thinners. Depending on what you take and why, you may be told to pause certain anticoagulants or antiplatelet drugs for a few days before the biopsy, though the specific instructions vary by drug and by your individual bleeding risk.

An IV line is placed in your arm before the procedure begins. This is used to deliver sedation and, if needed, pain medication. Most centers also attach monitoring equipment to track your heart rate, blood pressure, and oxygen levels throughout the procedure.

Sedation Options

Most EUS-guided biopsies are performed under either moderate (conscious) sedation or general anesthesia. With conscious sedation, you receive medications through the IV that make you drowsy and relaxed but not fully unconscious. You may have little or no memory of the procedure afterward, though some people recall fragments. General anesthesia renders you fully unconscious and is delivered by an anesthesiologist.

There is some evidence that general anesthesia can improve the chances of getting a definitive diagnosis. One study of 371 patients found that those under general anesthesia had an 83% rate of obtaining a cytological diagnosis compared with 73% in the conscious-sedation group, with an adjusted odds ratio of about 2.5 in favor of general anesthesia. Complication rates were the same between the two groups.³ The likely explanation is straightforward: a completely still patient allows the endoscopist to position the needle more precisely and take more passes without the patient shifting. That said, conscious sedation remains the standard at many centers, and your team will recommend one approach over the other based on the complexity of the case and your health history.

Propofol is one of the most common sedation agents used for these procedures. It is typically titrated, meaning the dose is adjusted continuously during the procedure to keep you at the right depth of sedation.⁴

The Procedure Step by Step

Once sedation takes effect, the endoscopist passes the echoendoscope, a flexible tube about the diameter of a finger, through your mouth and down through your esophagus and stomach. A tiny ultrasound transducer at the tip produces real-time images of the pancreas and surrounding structures. The endoscopist uses these images to identify the lesion and plan the safest needle path, avoiding blood vessels and the main pancreatic duct when possible.

A fine needle is then advanced through a channel in the scope and pushed through the wall of the stomach or duodenum directly into the target. The needle is moved back and forth within the lesion several times during each pass to loosen cells and capture tissue. Suction may be applied through the needle to help draw material into it. The needle is then withdrawn, and the sample is expelled onto a slide or into a collection container. This sequence, called a “pass,” is repeated multiple times. The number of passes depends on the needle type and whether tissue quality is being checked in real time, but two to four passes is common.

Newer techniques like elastography, which measures tissue stiffness in real time, can help guide the needle toward the most suspicious part of a mass. One approach uses a strain ratio to identify hard areas, then directs a 25-gauge needle specifically into those zones.⁵

Fine Needle Aspiration Versus Fine Needle Biopsy

You may hear your doctor mention FNA or FNB, and the distinction matters. Fine needle aspiration (FNA) uses a thin needle to suction out individual cells for examination under a microscope. It has been the standard approach for decades and works well for identifying cancer cells. Fine needle biopsy (FNB) uses a slightly different needle design, often with a side-cutting tip, that captures a small core of intact tissue rather than just loose cells.⁶

The practical advantage of FNB is that intact tissue lets pathologists see the architecture of the cells, not just the cells themselves. This is particularly useful when extra testing like immunohistochemical staining is needed to pin down an unusual diagnosis. In terms of overall accuracy, the two methods perform similarly. A study comparing 22-gauge FNA and FNB needles in small pancreatic lesions found no significant difference in diagnostic accuracy (about 93% versus 96%), but the FNB group needed fewer needle passes (a median of 2 versus 3) and had a higher rate of producing tissue suitable for histological analysis.⁷ Fewer passes generally means a shorter procedure and potentially less discomfort afterward.

Cost can differ between the two. One analysis found that FNB was not more cost-effective than FNA when FNA was paired with on-site evaluation of the sample, suggesting that the choice between the two should depend on what is available at your center and what your medical team is most experienced with.⁸ In resource-limited settings, FNA is often the more practical first-line option.⁹

On-Site Sample Evaluation

At some hospitals, a cytopathologist is present in the procedure room to examine samples under a microscope as they are collected. This is called rapid on-site evaluation, or ROSE. The idea is that the pathologist can tell the endoscopist in real time whether the sample contains enough diagnostic material or whether more passes are needed. ROSE can reduce the number of inconclusive results by catching inadequate samples before the procedure ends.

Interestingly, the diagnostic accuracy of the final result does not always differ significantly between procedures with and without ROSE. One single-center study found diagnostic accuracy of about 97% with ROSE and 96% without it. However, ROSE was independently associated with better diagnostic yield when accounting for the number of passes and slides obtained, suggesting its real benefit is in optimizing sample collection during the procedure rather than changing the final accuracy number.¹⁰ Not every center has ROSE available, and when newer FNB needles are used instead, a simpler visual check of the sample (macroscopic on-site evaluation) can perform comparably.¹¹

When a CT-Guided Percutaneous Biopsy Is Used Instead

Not every pancreatic biopsy goes through the digestive tract. In some situations, a radiologist inserts a needle through the skin of the abdomen under CT guidance. This percutaneous approach is typically chosen when EUS is not available, when a previous EUS biopsy was inconclusive, or when the anatomy of the lesion makes it easier to reach from outside the body.

The needle may pass through the mesentery or retroperitoneal fat to reach the pancreas, but sometimes the safest straight-line path goes through another organ entirely, such as the stomach, liver, or colon. A study of trans-organ biopsies found that this approach was safe and effective, with sensitivity around 91% and accuracy around 91%, and no major complications even when the needle crossed through the stomach or bowel. Minor bruising at the puncture site occurred in roughly 14% of cases.¹² When the lesion sits close to major blood vessels, fine needle aspiration may be preferred over core needle biopsy because the thinner needle is safer in that tight space.¹³

Percutaneous biopsy is done under local anesthesia with or without light sedation. You lie on a CT scanner table, and after numbing the skin, the radiologist advances the needle while periodically scanning to confirm its position. The procedure itself is usually quicker than EUS, but recovery involves lying still for a few hours while the team monitors for bleeding.

Risks Worth Understanding

As noted, the overall complication rate for EUS-guided biopsy is very low across large datasets.² But “low” is not “zero,” and certain situations raise the risk. The most clinically relevant complication is acute pancreatitis, inflammation of the pancreas triggered by the needle. A study of over 700 patients found that the risk jumped substantially when the needle had to pass through 5 millimeters or more of normal pancreatic tissue to reach the lesion, or when it crossed the main pancreatic duct. In that higher-risk group, about 9% developed pancreatitis afterward, compared with less than 1% when the needle path was shorter.¹⁴ This is one reason your endoscopist carefully plans the needle path using real-time imaging.

A concern that patients sometimes read about online is needle-tract seeding, the possibility that cancer cells could be dragged along the needle path and deposited in healthy tissue. This has been documented, with one estimate placing the incidence at about 1.4% for pancreatic cancer cases. The risk appears to increase with more biopsy attempts and more needle passes.¹⁵ The concern is somewhat more relevant for percutaneous biopsies, where the needle crosses a longer path through the abdominal wall, than for EUS biopsies, where the short path through the stomach wall is removed along with the tumor if the patient proceeds to surgery. In practice, the benefit of obtaining a tissue diagnosis almost always outweighs this small risk, but it is one reason doctors avoid unnecessary repeat biopsies when the diagnosis is already clear.

Recovery and What to Expect Afterward

After an EUS-guided biopsy, you spend one to two hours in a recovery area while the sedation wears off. Your throat may feel mildly sore from the scope, and some people experience bloating from the small amount of air introduced during the procedure. You should not drive for the rest of the day because of the lingering effects of sedation, so arrange for someone to take you home.

Mild abdominal discomfort in the hours afterward is common and does not usually signal a problem. Contact your medical team if you develop severe abdominal pain, fever, vomiting, or signs of bleeding such as dark or bloody stools. These symptoms are uncommon but warrant prompt evaluation. Most people return to normal activities the following day.

For percutaneous biopsies, recovery is similar. You may have some tenderness at the needle insertion site on your abdomen. A small bandage covers the puncture, and you are usually monitored for a few hours before discharge.

The Emotional Side of Waiting

The anxiety surrounding a pancreatic biopsy often has less to do with the procedure itself and more to do with what the results might show. Researchers have recognized that the fear and anxiety patients experience can be disproportionate to the actual physical risks of the biopsy. Waiting for results tends to trigger intrusive thoughts about a potential cancer diagnosis, which is understandably one of the most stressful possibilities a person can face.¹⁶ If you find the waiting period difficult, that is a normal response, not a sign of weakness. Some centers now offer pre-procedure educational materials, counseling, or other interventions designed to help manage this anxiety before and after the biopsy.

What Happens if Results Are Inconclusive

Roughly 10% of initial EUS-guided biopsies produce inconclusive results, meaning the pathologist cannot make a definitive diagnosis from the sample obtained.¹⁷ This does not mean the procedure failed entirely. It may mean the sample was too small, contained too much blood or debris, or came from a part of the mass that was not representative.

When this happens, a repeat EUS-guided biopsy is generally the recommended next step. Evidence suggests that repeating the procedure with specific technical adjustments can substantially improve the odds of a clear answer. Recommendations for the repeat procedure include using a 22-gauge FNB needle, performing at least four needle passes, and applying suction technique.¹⁸ Alternative options include CT-guided percutaneous biopsy, bile duct brushing during an ERCP procedure, or in some cases proceeding directly to surgical exploration if clinical suspicion for cancer is high enough.

If you receive inconclusive results, it is reasonable to ask your team specifically what made the sample inadequate and what changes they plan for the repeat attempt. Understanding why the first try fell short can make the decision to undergo a second procedure feel less like repeating a failure and more like a targeted correction.¹⁹

Liquid Biopsy and the Future of Pancreatic Diagnosis

You may have heard about liquid biopsy, a blood test that looks for tumor DNA, proteins, or other cancer markers circulating in the bloodstream. The appeal is obvious: a simple blood draw instead of a sedated procedure. For pancreatic cancer, though, liquid biopsy is not yet ready to replace tissue sampling. Current research positions it as a complementary tool rather than a substitute for the histopathological diagnosis that comes from actually examining tissue under a microscope, and its role in early detection remains poorly defined.²⁰

The challenge with pancreatic cancer is that many tumors shed very little genetic material into the blood, particularly at early stages when detection would matter most. Liquid biopsy may eventually find a role in monitoring treatment response or detecting recurrence after surgery, but for the foreseeable future, if your doctor needs to know what a pancreatic mass is, a needle biopsy remains the way to find out.